Skip to Main Content

Paper Details

The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies.
Multiple Sclerosis and Related Disorders
6
2021
EDSS, MS, MSBase, Natalizumab, fingolimod, natalizumab, patients, relapsing-remitting multiple sclerosis
Author NameAffiliation
Finn SellebjergCopenhagen University Hospital, Rigshospitalet Glostrup
Per Soelberg SørensenUniversity of Copenhagen, Rigshospitalet
Jeannette Lechner-ScottUniversity Newcastle, John Hunter Hospital
Marc DebouverieCentre hospitalier regional universitaire de Nancy
Jean PelletierAssistance publique des hopitaux de Marseille, Centre hospitalier de la Timone
Olivier Gout
Philippe CabreCentre hospitalier universitaire de Martinique
Helmut ButzkuevenCentral Clinical School, Monash University, The Alfred Hospital, Box Hill Hospital
  • 1 - 8

Datasets

Release 1.2